Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Intestinal fructose metabolism drives unsaturated fat absorption and synergizes with GLP-1 receptor agonism to promote weight loss.

bioRxiv : the preprint server for biology·2026

Same author

Dynamic visualization of physiological CaMKII activity using sensitive FRET biosensors.

bioRxiv : the preprint server for biology·2026

Same author

Very low-carbohydrate ketogenic diet in treatment-naïve women with endometrial cancer and overweight: a randomized feasibility study.

Nature communications·2026

Same author

Author Correction: Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function.

Nature·2026

Same author

Sex-specific disruptions in PKCγ signaling in a mouse model of spinocerebellar ataxia type 14.

JCI insight·2026

Same author

Publisher Correction: Motif-based substrate mapping of the receptor-like cytoplasmic kinase BIK1 reveals novel components and regulatory nodes of plant immunity.

Nature plants·2026

Search research articles

Related Experiment Video

Updated: Jun 9, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Targeting a common collaborator in cancer development.

Andrea P Myers¹, Lewis C Cantley

¹Division of Women's Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. apmyers@partners.org

Science Translational Medicine

|September 10, 2010

Summary

This summary is machine-generated.

Researchers found that certain breast and ovarian cancer cells respond synergistically to doxorubicin combined with a PI3K inhibitor (GDC-0941). This discovery could impact the clinical development of phosphatidylinositol 3-kinase pathway inhibitors for cancer treatment.

More Related Videos

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

Related Experiment Videos

Last Updated: Jun 9, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

Area of Science:

Oncology
Pharmacology
Molecular Biology

Background:

The phosphatidylinositol 3-kinase (PI3K) pathway is frequently dysregulated in various cancers, making it a key target for therapeutic intervention.
Doxorubicin is a widely used chemotherapy agent, but its efficacy can be limited by resistance mechanisms.
Developing targeted therapies that enhance the effectiveness of existing chemotherapeutics is a critical area of cancer research.

Purpose of the Study:

To identify cancer cell lines exhibiting a synergistic response to the combination of doxorubicin and a PI3K inhibitor.
To investigate the potential of combining doxorubicin with PI3K pathway inhibitors for improved cancer treatment outcomes.
To discuss the implications of these findings for the clinical development of PI3K inhibitors.

Main Methods:

Screening of breast and ovarian cancer cell lines for drug response.
Assessment of synergistic effects between doxorubicin and GDC-0941, a class IA PI3K inhibitor.
Analysis of cellular responses to drug combinations.

Main Results:

A specific subset of breast and ovarian cancer cell lines demonstrated a synergistic anti-cancer effect when treated with doxorubicin and GDC-0941.
The combination therapy showed enhanced efficacy compared to individual agents in sensitive cell lines.
These findings highlight the potential of targeting the PI3K pathway in conjunction with conventional chemotherapy.

Conclusions:

The combination of doxorubicin and the PI3K inhibitor GDC-0941 shows promise for treating specific breast and ovarian cancers.
These results warrant further investigation into the clinical utility of PI3K pathway inhibitors in combination regimens.
This study provides a rationale for the clinical development of PI3K inhibitors as a strategy to overcome chemoresistance and improve patient outcomes.